透析相关性低血压（IDH）会降低透析的疗效,给患者带来不适,其发生率为20%~30%[1]。IDH的诊断必须满足下述两个条件之一：透析过程中收缩压至少下降20 mm Hg（1mm Hg=0.133k Pa）,或平均动脉压至少下降10 mm Hg。IDH与多种临床事件相关...透析相关性低血压（IDH）会降低透析的疗效,给患者带来不适,其发生率为20%~30%[1]。IDH的诊断必须满足下述两个条件之一：透析过程中收缩压至少下降20 mm Hg（1mm Hg=0.133k Pa）,或平均动脉压至少下降10 mm Hg。IDH与多种临床事件相关,如心律失常、血管通路栓塞和脑血管循环、肠系膜循环和冠脉循环缺血[2]。展开更多
AIM： To evaluate the response to pegylated-interferon alpha 2a in chronic hepatitis C patients on chronic haemodialysis. METHODS： Ten patients with chronic C hepatitis were enrolled in this study. All had increased ...AIM： To evaluate the response to pegylated-interferon alpha 2a in chronic hepatitis C patients on chronic haemodialysis. METHODS： Ten patients with chronic C hepatitis were enrolled in this study. All had increased aminotransferases for more than 6 too, positive antiHCV antibodies and positive PCR HCV-RNA. We administrated Peg-Interferon alpha 2a 180 μg/wk for 48 wk. After 12 wk of treatment we evaluated the biochemical and early virological response （EVR）. At the end of the treatment we evaluated the biochemical response and 24 wk after the end of the treatment we evaluated the sustained virological response （SVR）. We monitored the sideeffects during the treatment. RESULTS： Two patients dropped out in the first 12 wk of treatment and 2 after the first 12 wk of treatment. After 12 wk of treatment, 7 out of 8 patients had biochemical response and EVR and 1 had biochemical response but persistent viremia. We had to reduce the dose of pegylated-interferon to 135 μg/wk in 2 cases. Three out of 6 （50%） patients had SVR 24 wk after the end of the treatment. Intention-to-treat analysis showed that 3 out of 10 patients （30%） had SVR. Side-effects occurred in most of the patients （flu-like syndrome, thrombocytopenia or leucopoenia）, but they did not impose the discontinuation of treatment. CONCLUSION： After 12 wk of treatment with Peg-Interferon alpha 2a （40 ku） in patients on chronic haemodialysis with chronic C hepatitis, EVR was obtained in 87.5% （7/8） of the cases. SVR was achieved in 50% of the cases （3/6 patients） that finished the 48 wk of treatment.展开更多
In this work, we evaluate the properties of solution casted polysulfone （PSf）/sulfonated polyethersulfone （SPES） blend membranes prepared by non-solvent induced phase inversion technique. The morphologies of these...In this work, we evaluate the properties of solution casted polysulfone （PSf）/sulfonated polyethersulfone （SPES） blend membranes prepared by non-solvent induced phase inversion technique. The morphologies of these blend membranes, observed using scanning electron microscopy （SEM） and atomic force microscopy （AFM） imaging, indicated a smoother skin layer and an increased number of highly interconnected pores in the sub layer. The efficacy of the prepared membranes was evaluated in terms of porosity, ultrafiltration rate （UFR）, molecular weight cut-off （MWCO） and mean pore size. The hydrophilicity of these membranes was in consonance with contact angle values. It was observed that the selectivity and the UFR of the blend membranes were higher when compared to pristine membranes. Furthermore, these blend membranes demonstrated an increase in biocompatibility - prolonged blood clotting time, suppressed platelet adhesion, reduced protein adsorption and lower complement activation. These membranes were also investigated for uremic solute removal. Diffusive permeability of middle molecular weight cytochrome-c revealed an increase from 8 × 10 ^-4 cm·s ^-1 to 18 × 10^-4 cm· s^- and illustrates the possibility that these sulfonated PES/PSf blend membranes can be used to prepare membrane modules for hemodialysis applications.展开更多
文摘透析相关性低血压（IDH）会降低透析的疗效,给患者带来不适,其发生率为20%~30%[1]。IDH的诊断必须满足下述两个条件之一：透析过程中收缩压至少下降20 mm Hg（1mm Hg=0.133k Pa）,或平均动脉压至少下降10 mm Hg。IDH与多种临床事件相关,如心律失常、血管通路栓塞和脑血管循环、肠系膜循环和冠脉循环缺血[2]。
文摘AIM： To evaluate the response to pegylated-interferon alpha 2a in chronic hepatitis C patients on chronic haemodialysis. METHODS： Ten patients with chronic C hepatitis were enrolled in this study. All had increased aminotransferases for more than 6 too, positive antiHCV antibodies and positive PCR HCV-RNA. We administrated Peg-Interferon alpha 2a 180 μg/wk for 48 wk. After 12 wk of treatment we evaluated the biochemical and early virological response （EVR）. At the end of the treatment we evaluated the biochemical response and 24 wk after the end of the treatment we evaluated the sustained virological response （SVR）. We monitored the sideeffects during the treatment. RESULTS： Two patients dropped out in the first 12 wk of treatment and 2 after the first 12 wk of treatment. After 12 wk of treatment, 7 out of 8 patients had biochemical response and EVR and 1 had biochemical response but persistent viremia. We had to reduce the dose of pegylated-interferon to 135 μg/wk in 2 cases. Three out of 6 （50%） patients had SVR 24 wk after the end of the treatment. Intention-to-treat analysis showed that 3 out of 10 patients （30%） had SVR. Side-effects occurred in most of the patients （flu-like syndrome, thrombocytopenia or leucopoenia）, but they did not impose the discontinuation of treatment. CONCLUSION： After 12 wk of treatment with Peg-Interferon alpha 2a （40 ku） in patients on chronic haemodialysis with chronic C hepatitis, EVR was obtained in 87.5% （7/8） of the cases. SVR was achieved in 50% of the cases （3/6 patients） that finished the 48 wk of treatment.
基金supported by the Department of Science and Technology (DST),Government of India (IDP/MED/2010/17/2(General)
文摘In this work, we evaluate the properties of solution casted polysulfone （PSf）/sulfonated polyethersulfone （SPES） blend membranes prepared by non-solvent induced phase inversion technique. The morphologies of these blend membranes, observed using scanning electron microscopy （SEM） and atomic force microscopy （AFM） imaging, indicated a smoother skin layer and an increased number of highly interconnected pores in the sub layer. The efficacy of the prepared membranes was evaluated in terms of porosity, ultrafiltration rate （UFR）, molecular weight cut-off （MWCO） and mean pore size. The hydrophilicity of these membranes was in consonance with contact angle values. It was observed that the selectivity and the UFR of the blend membranes were higher when compared to pristine membranes. Furthermore, these blend membranes demonstrated an increase in biocompatibility - prolonged blood clotting time, suppressed platelet adhesion, reduced protein adsorption and lower complement activation. These membranes were also investigated for uremic solute removal. Diffusive permeability of middle molecular weight cytochrome-c revealed an increase from 8 × 10 ^-4 cm·s ^-1 to 18 × 10^-4 cm· s^- and illustrates the possibility that these sulfonated PES/PSf blend membranes can be used to prepare membrane modules for hemodialysis applications.
